Last edition
News about "metabolic dysfunction-associated steatohepatitis ("
Emcure Receives CDSCO Nod to Expand Poviztra's Use for MASH Indication
Emcure has received CDSCO approval to expand Poviztra's use for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), addressing a major unmet need in progressive liver disease treatment.
Metabolic Dysfunction-associated Steatohepatitis ( | 21/07/2026 | By News Bureau
Japan Approves Wegovy for MASH
Wegovy subcutaneous injection has been approved in Japan for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), becoming the first approved therapy for the disease in the country.
Metabolic Dysfunction-Associated Steatohepatitis ( | 22/06/2026 | By News Bureau
Novo Nordisk to Acquire Akero Therapeutics Alongside Promising MASH Therapy Efruxifermin
Danish pharma giant Novo Nordisk has signed a definitive agreement to acquire Akero Therapeutics, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for serious metabolic diseases.
Metabolic Dysfunction-associated Steatohepatitis ( | 10/10/2025 | By Dineshwori | 373
Roche to Acquire 89bio in Deal Worth Up to USD 3.5 Billion
Roche has entered into a merger agreement to acquire 89bio, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases.
Metabolic Dysfunction-associated Steatohepatitis ( | 18/09/2025 | By Dineshwori | 254
Novo Nordisk's Wegovy Approved for Treatment of MASH in Adults with Liver Fibrosis
The US FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, according to Novo Nordisk.
Metabolic Dysfunction-associated Steatohepatitis ( | 16/08/2025 | By Dineshwori | 371
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy